BDBM111123 US10017516, Compound 2::US9682983, 2

SMILES C[C@H]1CNC[C@@H](C)N1c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12

InChI Key InChIKey=SHWKNOUREYUNBF-UHFFFAOYSA-N

Data  20 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 111123   

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 1.68E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 9nMAssay Description:Inhibition of ALK2 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2020
Entry Details Article
PubMed
TargetBone morphogenetic protein receptor type-1A(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 7nMAssay Description:Inhibition of ALK3 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2020
Entry Details Article
PubMed
TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 226nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 330nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 110nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 6.5nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 8.60nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 213nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 5.80nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 556nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 9.10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 5.80nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 213nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 1.68E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 556nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 9.10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent